A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics

被引:24
作者
Awada, Hassan [1 ]
Thapa, Bicky [2 ]
Awada, Hussein [1 ]
Dong, Jing [2 ]
Gurnari, Carmelo [1 ]
Hari, Parameswaran [2 ]
Dhakal, Binod [2 ]
机构
[1] Cleveland Clin, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
关键词
multiple myeloma; plasma cell dyscrasia; genomics; risk stratification; prognosis; MONOCLONAL GAMMOPATHY; MOLECULAR CLASSIFICATION; LONG-TERM; UNDETERMINED SIGNIFICANCE; HOMOZYGOUS DELETION; RAS MUTATIONS; RISK; HETEROGENEITY; BORTEZOMIB; PATHOGENESIS;
D O I
10.3390/cells10081961
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Multiple myeloma (MM) is a blood cancer characterized by the accumulation of malignant monoclonal plasma cells in the bone marrow. It develops through a series of premalignant plasma cell dyscrasia stages, most notable of which is the Monoclonal Gammopathy of Undetermined Significance (MGUS). Significant advances have been achieved in uncovering the genomic aberrancies underlying the pathogenesis of MGUS-MM. In this review, we discuss in-depth the genomic evolution of MM and focus on the prognostic implications of the accompanied molecular and cytogenetic aberrations. We also dive into the latest investigatory techniques used for the diagnoses and risk stratification of MM patients.
引用
收藏
页数:15
相关论文
共 108 条
[1]   Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma [J].
Abdallah, Nadine ;
Baughn, Linda B. ;
Rajkumar, S. Vincent ;
Kapoor, Prashant ;
Gertz, Morie A. ;
Dispenzieri, Angela ;
Lacy, Martha Q. ;
Hayman, Suzanne R. ;
Buadi, Francis K. ;
Dingli, David ;
Go, Ronald S. ;
Hwa, Yi L. ;
Fonder, Amie ;
Hobbs, Miriam ;
Lin, Yi ;
Leung, Nelson ;
Kourelis, Taxiarchis ;
Warsame, Rahma ;
Siddiqui, Mustaqeem ;
Lust, John ;
Kyle, Robert A. ;
Ketterling, Rhett ;
Bergsagel, Leif ;
Greipp, Patricia ;
Kumar, Shaji K. .
CLINICAL CANCER RESEARCH, 2020, 26 (24) :6581-6588
[2]   Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response [J].
Abdallah, Nadine ;
Rajkumar, S. Vincent ;
Greipp, Patricia ;
Kapoor, Prashant ;
Gertz, Morie A. ;
Dispenzieri, Angela ;
Baughn, Linda B. ;
Lacy, Martha Q. ;
Hayman, Suzanne R. ;
Buadi, Francis K. ;
Dingli, David ;
Go, Ronald S. ;
Hwa, Yi L. ;
Fonder, Amie ;
Hobbs, Miriam ;
Lin, Yi ;
Leung, Nelson ;
Kourelis, Taxiarchis ;
Warsame, Rahma ;
Siddiqui, Mustaqeem ;
Lust, John ;
Kyle, Robert A. ;
Bergsagel, Leif ;
Ketterling, Rhett ;
Kumar, Shaji K. .
BLOOD CANCER JOURNAL, 2020, 10 (08)
[3]   Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies [J].
Abdel-Wahab, Omar ;
Klimek, Virginia M. ;
Gaskell, Alisa A. ;
Viale, Agnes ;
Cheng, Donavan ;
Kim, Eunhee ;
Rampal, Raajit ;
Bluth, Mark ;
Harding, James J. ;
Callahan, Margaret K. ;
Merghoub, Taha ;
Berger, Michael F. ;
Solit, David B. ;
Rosen, Neal ;
Levine, Ross L. ;
Chapman, Paul B. .
CANCER DISCOVERY, 2014, 4 (05) :538-545
[4]   Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].
Adjei, Alex A. ;
Cohen, Roger B. ;
Franklin, Wilbur ;
Morris, Clive ;
Wilson, David ;
Molina, Julian R. ;
Hanson, Lorelei J. ;
Gore, Lia ;
Chow, Laura ;
Leong, Stephen ;
Maloney, Lara ;
Gordon, Gilad ;
Simmons, Heidi ;
Marlow, Allison ;
Litwiler, Kevin ;
Brown, Suzy ;
Poch, Gregory ;
Kane, Katie ;
Haney, Jerry ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146
[5]   Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study [J].
Amorim, Sandy ;
Stathis, Anastasios ;
Gleeson, Mary ;
Iyengar, Sunil ;
Magarotto, Valeria ;
Leleu, Xavier ;
Morschhauser, Franck ;
Karlin, Lionel ;
Broussais, Florence ;
Rezai, Keyvan ;
Herait, Patrice ;
Kahatt, Carmen ;
Lokiec, Francois ;
Salles, Gilles ;
Facon, Thierry ;
Palumbo, Antonio ;
Cunningham, David ;
Zucca, Emanuele ;
Thieblemont, Catherine .
LANCET HAEMATOLOGY, 2016, 3 (04) :E196-E204
[6]   Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma [J].
Annunziata, Christina M. ;
Davis, R. Eric ;
Demchenko, Yulia ;
Bellamy, William ;
Gabrea, Ana ;
Zhan, Fenghuang ;
Lenz, Georg ;
Hanamura, Ichiro ;
Wright, George ;
Xiao, Wenming ;
Dave, Sandeep ;
Hurt, Elaine M. ;
Tan, Bruce ;
Zhao, Hong ;
Stephens, Owen ;
Santra, Madhumita ;
Williams, David R. ;
Dang, Lenny ;
Barlogie, Bart ;
Shaughnessy, John D., Jr. ;
Kuehl, W. Michael ;
Staudt, Louis M. .
CANCER CELL, 2007, 12 (02) :115-130
[7]   Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors [J].
Avet-Loiseau, H ;
Gerson, F ;
Magrangeas, F ;
Minvielle, S ;
Harousseau, JL ;
Bataille, R .
BLOOD, 2001, 98 (10) :3082-3086
[8]   Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop [J].
Bagratuni, Tina ;
Sklirou, Aimilia D. ;
Kastritis, Efstathios ;
Liacos, Christine Ivy ;
Spilioti, Christina ;
Eleutherakis-Papaiakovou, Evangelos ;
Kanellias, Nikolaos ;
Gavriatopoulou, Maria ;
Terpos, Evangelos ;
Trougakos, Ioannis P. ;
Dimopoulos, Meletios A. .
SCIENTIFIC REPORTS, 2019, 9 (1)
[9]   Darwinian evolution and tiding clones in multiple myeloma [J].
Bahlis, Nizar J. .
BLOOD, 2012, 120 (05) :927-928
[10]   A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6 [J].
Baughn, Linda B. ;
Di Liberto, Maurizio ;
Wu, Kaida ;
Toogood, Peter L. ;
Louie, Tracey ;
Gottschalk, Rachel ;
Niesvizky, Ruben ;
Cho, Hearn ;
Ely, Scott ;
Moore, Malcolm A. S. ;
Chen-Kiang, Selina .
CANCER RESEARCH, 2006, 66 (15) :7661-7667